# Shanghai Enkai Cell Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-enkai-cell-technology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.nk-celltech.com
- Total disclosed funding: $29M
- Latest round: Series A (Jul 9, 2025)
- Investors on record: 11

## About

Established in 2020 and based in Shanghai, China, Shanghai Enkai Cell Technology Co., Ltd  is a cellular drug discovery and development company. The founder of this company, Zhigang Tian, is the founding director of the Institute of Immunology at the University of Science and Technology of China (USTC) and director of the Key Laboratory of Innate Immunity and Chronic Diseases at the Chinese Academy of Sciences (CAS). In November 2024, it closed a series A++ funding. The company’s main business is the R&D and production of innovative cell drugs based on NK cells. The company’s self-developed products include a series of original intelligent NK cell products under the ABCDE-NK® strategic platform, such as technologies and products in four major categories and twelve series. Its products are used in the field of treating major clinical diseases. Shanghai Enkai Cell Technology Co., Ltd generates revenue by providing NK cell-based immunotherapy solutions and related cell products. The company will use the series A++ funding to accelerate the development and clinical trial process of the pipeline of cellular drug products under development. In July 2025, Shanghai Enkai Cell Technology Co., Ltd raised nearly CNY 100 million of Series A+++ funding from new investor Pudong Capital and Zhongke Xianjin Fund.

## Funding rounds

- Series A, Jul 9, 2025, $14M — Pudong Capital, Zhongke Xianjin Fund
- Series A, Nov 22, 2024 — Yijin Capital, 3SBio Inc., Shanghai Zhangjiang Technology Venture Investment Co.,Ltd.
- Series A, Jul 1, 2022, $15M — Huagai Capital, Qiaojing Capital, Qiandao Investment Fund Management, CAS Venture Capital, Sirius Holding Group, Cheng Yi Capital

## Investors

- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- Qiaojing Capital (https://capitalatlas.ai/funds/qiaojing-capital) — Series A
- Qiandao Investment Fund Management (https://capitalatlas.ai/funds/qiandao-investment-fund-management) — Series A
- CAS Venture Capital (https://capitalatlas.ai/funds/cas-venture-capital) — Series A
- Sirius Holding Group (https://capitalatlas.ai/funds/sirius-holding-group) — Series A
- Cheng Yi Capital (https://capitalatlas.ai/funds/cheng-yi-capital) — Series A
- Yijin Capital (https://capitalatlas.ai/funds/yijin-capital) — Series A
- 3SBio Inc. — Series A
- Shanghai Zhangjiang Technology Venture Investment Co.,Ltd. — Series A
- Pudong Capital (https://capitalatlas.ai/funds/pudong-capital) — Series A
- Zhongke Xianjin Fund (https://capitalatlas.ai/funds/zhongke-xianjin-fund) — Series A